Soligenix, Inc. (SNGX)
| Market Cap | 27.31M |
| Revenue (ttm) | 869,409 |
| Net Income (ttm) | -13.39M |
| Shares Out | 42.87M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,809 |
| Open | 0.650 |
| Previous Close | 0.646 |
| Day's Range | 0.620 - 0.664 |
| 52-Week Range | 0.600 - 2.480 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 4.88 (+666.1%) |
| Earnings Date | Nov 11, 2021 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This se...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for Soligenix stock is "Strong Buy" and the 12-month stock price forecast is 4.88.
News
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)
New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good ne...
Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
PRINCETON, N.J., Jan. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Soligenix to Present at Upcoming Investor Conferences
PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
PRINCETON, N.J., Jan. 4, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the c...
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and...
PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...
Highlights and Insights into Soligenix
Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized VaccinesNew York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biote...
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorde...
PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic
COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta VariantsNew York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and ad...
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Va...
PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...
Soligenix To Test Synthetic Hypericin In Psoriasis Patients
Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Relat...
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...
Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics
Soligenix discusses its contribution to addressing future serious public health threats in a podcastNew York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has a...
SNGX Stock: The Big FDA News Giving Biotech Penny Stock Soligenix a Boost
Soligenix (SNGX) stock is roaring higher on Thursday thanks to some positive news from the U.S. Food and Drug Administration today. The post SNGX Stock: The Big FDA News Giving Biotech Penny Stock Solig...
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. "T...
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen condit...
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Plat...
PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates
Soligenix Inc (NASDAQ: SNGX) announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform presentation. Data from ...
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...